Study S000647

A Randomised, Double-blind, Placebo-controlled, Dose Escalation Trial of Single Doses of NNC90-1170 to Assess Tolerability, Pharmacokinetics, Pharmacodynamics and Absolute Bioavailability in Healthy Male Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01507272
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 34
Start: 1999-03
Primary completion: 1999-12
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Healthy
Interventions: DRUG:liraglutide; DRUG:placebo
Results posted: FALSE

Registered primary outcomes

AUC (area under the curve) []

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0026685	Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative. Agersø H, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences	2003	Other trial	PMID 12791417 DOI	registry reference RESULT:12791417
R0027230	Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Elbrønd B, Diabetes care	2002	Randomized trial	PMID 12145241 DOI	registry reference RESULT:12145241